- Trials with a EudraCT protocol (2,266)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
2,266 result(s) found for: Cell Line.
Displaying page 1 of 114.
EudraCT Number: 2012-000473-23 | Sponsor Protocol Number: RETRY | Start Date*: 2012-05-29 | |||||||||||
Sponsor Name:GIOM - Gruppo Italiano Oncologia Nefrologica | |||||||||||||
Full Title: PHASE II STUDY OF SUNITINIB AS RECHALLENGE THIRD-LINE THERAPY IN METASTATIC RENAL CANCER | |||||||||||||
Medical condition: Metastatic renal cancer thrid-line therapy already treated in fist-line therapy with Sunitinib. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024468-16 | Sponsor Protocol Number: BO25460 | Start Date*: 2011-06-29 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled Phase III study of first-line maintenance Tarceva vs Tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (... | ||||||||||||||||||
Medical condition: Advanced (Stage IIIB or IV) NSCLC previously treated with 4 cycles of a platinum-based chemotherapy (for Traceva®). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) HU (Completed) CZ (Completed) LV (Completed) LT (Completed) NL (Completed) FR (Completed) BG (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-003796-20 | Sponsor Protocol Number: HOVON 77 | Start Date*: 2007-01-03 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission f... | |||||||||||||
Medical condition: patients with diffuse Large B-Cell lymphoma, CD20-positive | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020447-13 | Sponsor Protocol Number: CRAD001L2404 | Start Date*: 2012-08-17 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label, multicenter phase II study to examine the efficacy and safety of everolimus as second-line therapy in the treatment of patients with metastatic renal cell carcinoma | |||||||||||||
Medical condition: Metastatic Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003079-32 | Sponsor Protocol Number: CC-5013-CLL-008 | Start Date*: 2009-06-19 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: ESTUDIO FASE 3, MULTICÉNTRICO, ALEATORIZADO, ABIERTO Y DE GRUPOS PARALELOS PARA VALORAR LA EFICACIA Y SEGURIDAD DE LENALIDOMIDA (REVLIMID®) FRENTE A CLORAMBUCILO COMO TERAPIA DE PRIMERA LÍNEA EN PA... | |||||||||||||
Medical condition: TERAPIA DE PRIMERA LÍNEA EN PACIENTES ANCIANOS CON LEUCEMIA LINFOCÍTICA CRÓNICA DE CÉLULAS B NO TRATADOS PREVIAMENTE (FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH B-CELL CHRON... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) BE (Completed) PT (Completed) CZ (Completed) GB (Completed) HU (Completed) IT (Completed) FR (Completed) NL (Completed) DK (Completed) SK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006323-31 | Sponsor Protocol Number: D1532C00016 | Start Date*: 2009-05-19 | |||||||||||||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||
Full Title: D1532C00016: A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared with Docetaxel Alone, in 2nd Line... | |||||||||||||||||||||||
Medical condition: 2nd Line Patients with KRAS Mutation Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) BG (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005011-18 | Sponsor Protocol Number: 09072008-13772 | Start Date*: 2008-11-05 | |||||||||||
Sponsor Name:Deutsche Krebsgesellschaft e.V. | |||||||||||||
Full Title: A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advan... | |||||||||||||
Medical condition: First-line advanced / metastatic renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002539-25 | Sponsor Protocol Number: ATOM 019 | Start Date*: 2004-12-10 | |||||||||||
Sponsor Name:UNIVERSITA' DEGLI STUDI DI UDINE | |||||||||||||
Full Title: Randomized phase II trial of second-line chemotherapy with oxaliplatin and docetaxel vs. docetaxel in patients with advanced non-small cell lung cancer (NSCLC) | |||||||||||||
Medical condition: Second-line chemotherapy in advanced non small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003870-16 | Sponsor Protocol Number: AlloTor | Start Date*: 2008-09-22 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: A PILOT STUDY OF SEQUENTIAL, NON-MYELOABLATIVE HLA-IDENTICAL SIBLING DONOR ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWED BY IV TEMSIROLIMUS IN PATIENTS WITH ADVANCED, TKI-REFRACTORY CLEAR-CELL RENA... | |||||||||||||
Medical condition: PATIENTS WITH ADVANCED, TKI-REFRACTORY CLEAR-CELL RENAL CELL CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001264-37 | Sponsor Protocol Number: 1200.40 | Start Date*: 2008-11-20 | |||||||||||
Sponsor Name:BOEHRINGER ING. | |||||||||||||
Full Title: A Phase II single-arm trial of BIBW 2992(Tovok) in EGFR FISH positive non-small cell lung cancer patients | |||||||||||||
Medical condition: Patients affected by NSCLC EGFR FISH positive. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003416-23 | Sponsor Protocol Number: CRAD001LDE43 | Start Date*: 2012-03-12 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: An open label, single arm trial to evaluate patients with metastatic renal cell carcinoma treated with everolimus after failure of first line therapy with sunitinib or pazopanib | |||||||||||||
Medical condition: metastatic renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002917-38 | Sponsor Protocol Number: SG040-0005 | Start Date*: 2008-02-20 | |||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||
Full Title: A Randomised, Phase IIb Placebo-controlled Study of R-ICE Chemotherapy (Rituximab, Isofosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Se... | |||||||||||||
Medical condition: Diffuse Large B-cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Prematurely Ended) BE (Completed) HU (Completed) FR (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000528-42 | Sponsor Protocol Number: 0601 | Start Date*: 2008-07-17 | |||||||||||
Sponsor Name:Poniard Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Controlled Phase III Trial of Picoplatin and Best Supportive Care (BSC) versus BSC Alone in Patients with Small Cell Lung Cancer (SCLC), Refractory or Progressive within Six Months of... | |||||||||||||
Medical condition: Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) LV (Completed) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003989-18 | Sponsor Protocol Number: AMR PH GL 2007 CL 001 | Start Date*: 2008-04-24 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of ... | |||||||||||||
Medical condition: Extensive or limited and sensitive or refractory SCLC after failure of first-line chemotherapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) DK (Completed) HU (Completed) NL (Completed) AT (Completed) CZ (Completed) IT (Completed) FR (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003729-18 | Sponsor Protocol Number: LENALIDOMIDEand DLBCL | Start Date*: 2008-09-25 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: A phase II trial to evaluate the safety and activity of single-agent lenalidomide given as maintenance therapy after response to second-line therapy in patients with relapsed diffuse large B cell l... | |||||||||||||
Medical condition: patients affected by diffused linfoma with big cells | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011056-21 | Sponsor Protocol Number: CRAD001L2202 | Start Date*: 2009-08-10 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 ... | |||||||||||||
Medical condition: Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) ES (Completed) GB (Completed) DE (Completed) IT (Completed) FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001097-18 | Sponsor Protocol Number: CA209-331 | Start Date*: 2015-09-15 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinumbased First Line Chemotherapy | |||||||||||||||||||||||
Medical condition: Relapsed Small Cell Lung Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: CZ (Completed) AT (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) HU (Completed) GR (Completed) PL (Completed) ES (Completed) FR (Completed) RO (Ongoing) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005968-90 | Sponsor Protocol Number: TORCH | Start Date*: 2007-02-26 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE | |||||||||||||
Full Title: An international multicenter randomized phase III study of first-line Erlotinib followed by second-line Cisplatin Gemcitabine versus first-line Cisplatin Gemcitabine followed by second-line Er... | |||||||||||||
Medical condition: advanced non small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003713-18 | Sponsor Protocol Number: C14018 | Start Date*: 2014-09-15 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for... | |||||||||||||
Medical condition: Relapsed or Refractory Small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004146-18 | Sponsor Protocol Number: CCR3549 | Start Date*: 2011-11-09 | |||||||||||
Sponsor Name:The Royal Marsden NHS Foundation Trust | |||||||||||||
Full Title: Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre rando... | |||||||||||||
Medical condition: T-cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.